CLINICAL TRIAL SUMMARY

MDACC Study No:RTOG1203 (clinicaltrials.gov NCT No: NCT01672892)
Title:A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
Principal Investigator:Ann Klopp
Treatment Agent:Cisplatin; Radiation
Study Status:Open
Study Description:The goal of this clinical research study is to find out if using a radiation
delivery method called intensity-modulated radiation therapy (IMRT) leads to
fewer and/or less severe gastrointestinal side effects (such as diarrhea) than
standard radiation delivery.

IMRT is designed to give radiation to the areas that your doctor thinks may
have cancer cells. It is also designed to lower the amount of radiation that
nearby normal tissues (such as the small and large intestine) receive.

Hide details for General InformationGeneral Information

Disease Group:Cervix; Endometrium
Phase of Study:Phase III
Treatment Agents:Cisplatin
Radiation
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NRG Oncology
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Ann Klopp
Dept:Radiation Oncology
For Clinical Trial Enrollment:713-563-6830
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults